Skip to main content

COVID-19

Global SECURE-IBD trial on IBD drugs and COVID shows that severe COVID-19 outcomes were not associated with the use of biologics and mesalamine/sulfasalazine, AZA, 6MP, MTX combo Rx or biologics (TNFi, IL-12/23, IL-23, integrin inhib) https://t.co/MO4i5ngKkr

Dr. John Cush @RheumNow( View Tweet )

Sep 27, 2021
Prospective study of 77 RA patients in remission --> vax w/ BNT162b2 (BioNTech-Pfizer) (w/ temp D/C of DMARDs per ACR) found a vaccine-related flare rate of 7/8% (6 pts) w/ 5/6 flares after 2nd dose (2.6 days), resolved w/in 2 wks https://t.co/YOL3YVArvG #RheumNow https://t.co/dxRWhu8CJX
Dr. John Cush @RheumNow( View Tweet )
Sep 27, 2021
Can I get the INFLUENZA and COVID Vaccines together? The CDC says: "YES...both vaccines can be given at the same visit, people should follow the recommended schedule for either vaccine.... ideally get a flu vaccine by the end of October." https://t.co/T49zm6Cxyc

Dr. John Cush @RheumNow( View Tweet )

Sep 27, 2021
New study on #COVID19Vaccine in autoimmune cytopenias 🩸7.4% had clinically significant ⬇️ in counts 🩸 All successfully managed w/steroids & transfusion 🩸 Mild ⬇️ in 10% AIHA and 20% ITP ⭐️Vaccination safe with close monitoring⭐️ https://t.co/qGZe6LiPKz

AmericanJournalofHematology @AjHematology( View Tweet )

Sep 26, 2021

RheumNow Podcast – I Wanna New Drug.V2 (9.24.2021)

Sep 23, 2021

Almost three years ago to the day, I did a podcast entitled, "I wanna new drug." As I go over this week's podcast, I want to say it again. I want a new drug safe enough to use during pregnancy, for PMR, for GVHD, and more. I'm going to cover these, and other topics including lupus, COVID

Read Article
Prospective study of 77 RA patients in remission --> vax w/ BNT162b2 (BioNTech-Pfizer) (w/ temp D/C of DMARDs per ACR) found a vaccine-related flare rate of 7/8% (6 pts) w/ 5/6 flares after 2nd dose (2.6 days), resolved w/in 2 wks https://t.co/YOL3YVS2ne

Dr. John Cush @RheumNow( View Tweet )

Sep 22, 2021
MMWR reports real world vax efficacy in 3,689 adults (21 states) found better results w/ Moderna (93%) than Pfizer (88%) than Janssen (71%). 2 dose mRNA vaccines were more effective than 1 dose Janssen COVID vaccine https://t.co/phmPdB9dTW

Dr. John Cush @RheumNow( View Tweet )

Sep 21, 2021
Maker Trade name Generic PFIZER Comirnaty Pfizer-BioNTech COVID-19 Vaccine FDA approved MODERNA Spikevax Moderna COVID-19 Vaccine - EUA currently J&J (pending) Janssen COVID-19 Vaccine- EUA currently https://t.co/MM7XiSCczl

Dr. John Cush @RheumNow( View Tweet )

Sep 21, 2021

Worrisome Maternal Mortality with COVID-19 Infection

Sep 20, 2021

Maternal and fetal outcomes during the COVID-19 pandemic have not been well studied; yet a new retrospective study from Mexico indicates that during the pandemic maternal mortality increased by nearly 57%, with COVID-19 as the cause in 23% of cases.



This surveillance study examined

Read Article
Addendum: Other conditions w/ a 1.2-2 fold higher risk of COVID death (admission) were CKD, hematologic cancer, epilepsy, COPD, CVD, stroke, atrial fibrillation, CHF, thromboembolism, PVD, type 2 diabetes. https://t.co/bbDsb1zLhX

Dr. John Cush @RheumNow( View Tweet )

Sep 20, 2021
Addendum: COVID deaths increased w/ age, deprivation, male, Indian & Pakistanis. Highest risk w/ Down’s syndr (HR 12.7), renal transplant (8.1), sickle cell (7.7), Nursing home (4.1), chemotherapy (4.3), HIV/AIDS (3.3), liver cirrhosis (3), CNS dz (2.6) https://t.co/bbDsb1zLhX

Dr. John Cush @RheumNow( View Tweet )

Sep 20, 2021
Breakthrough infections from UK QResarch database: Among 6.95 million vaccinated, 74.1% recv two vaccine doses, there were 2031 covid-19 deaths & 1929 hosp admissions; ~4.0% deaths & admissions were >14 days after 2nd dose https://t.co/bbDsb1zLhX

Dr. John Cush @RheumNow( View Tweet )

Sep 20, 2021
Analysis of existing #COVID data - as of 7/15/21, 114.9 million adults infected with COVID-19 in US. Overall population immunity (Infx+vax) is 62%, highest in adults >65yrs (77.2%); lowest in children <12 yrs (17.9%) https://t.co/EYiBUaQBLY

Dr. John Cush @RheumNow( View Tweet )

Sep 20, 2021
ICYMI: American College of OBs & GYNS and the Society for Maternal-Fetal Medicine both enthusiastically endorse COVID Vaccination of pregnant women, given the delta variant, low vax rates in Preg women and poor COVID outcomes in preg. https://t.co/AmP5eOEgr3 #RheumNow https://t.co/wXeT1KDCrJ
Dr. John Cush @RheumNow( View Tweet )
Sep 19, 2021
In case you missed it… Breakthrough COVID infection. Breakthrough brilliance in a KOL A must read from Len Calabrese https://t.co/2Ljzau5nBG #RheumNow

Dr. John Cush @RheumNow( View Tweet )

Sep 19, 2021
ICYMI: Probenecid, an OAT3 inhibitor, has inhibitory effects on RNA viruses (influenza, RSV) & decreases ACE2 expression. May have utility in COVID-19 as it was shown to inhibit SARS-CoV-2 replication in animal models https://t.co/MClSjpqpSa #RheumNow

Dr. John Cush @RheumNow( View Tweet )

Sep 18, 2021
Another non stellar result for remdesivir Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): P3, randomised, controlled, open-label trial ⁦@TheLancetInfDis⁩ https://t.co/kNSNj9RM4K

Dr Philip Robinson @philipcrobinson( View Tweet )

Sep 17, 2021

RheumNow Podcast – Do More DMARDs Mean More Switching? (9.17.2021)

Sep 16, 2021

Smartphones and diet; COVID-19 and the numbers - reassuring or not, and what about masks?; and do more drugs mean more switching, less persistence, and patient adherence goes up...or down? All this and more news and journal reports in this week's episode.

Read Article
American College of OBs & GYNS and the Society for Maternal-Fetal Medicine both enthusiastically endorse COVID Vaccination of pregnant women, given the delta variant, low vax rates in Preg women and poor COVID outcomes in preg. https://t.co/AmP5eOEgr3

Dr. John Cush @RheumNow( View Tweet )

Sep 16, 2021

Effect of Diet on COVID Outcomes

Sep 15, 2021

A smartphone-based symptom study of COVID-19 patients has shown that a healthy plant-based diet was associated with lower risk and severity of COVID-19, especially amongst those living in areas with higher socioeconomic deprivation.



Data was collected from 592,571 individuals

Read Article
Study of 265 students w/ a positive COVID-19 test looked at 378 close contacts. Infx rates w both persons masked -7.7%, but when unmasked-32.4% (aORs = 4.9;) https://t.co/fYdH33JbWR

Dr. John Cush @RheumNow( View Tweet )

Sep 15, 2021
Baricitinib & Tofacitinib are effective in COVID-19 pts. These drugs are expensive; baricitinib is $44/tablet, but much lower for generics worldwide. 14 day course of TOFA would be >$1,400 in the US (but $600 in France, $25 in India) https://t.co/r2cn1H2z8i

Dr. John Cush @RheumNow( View Tweet )

Sep 14, 2021
MMWR reports that during the COVID Delta variant era, Vaccination against COVID-19: - Reduces risk of COVID-19 infection 5X - Reduces risk of COVID-19 Hospitalization >10X - Reduces risk of COVID-19 DEATH 10X https://t.co/rMRY84xX5F

Dr. John Cush @RheumNow( View Tweet )

Sep 13, 2021
Probenecid, an OAT3 inhibitor, has inhibitory effects on RNA viruses (influenza, RSV) & decreases ACE2 expression. May have utility in COVID-19 as it was shown to inhibit SARS-CoV-2 replication in animal models https://t.co/MClSjpqpSa

Dr. John Cush @RheumNow( View Tweet )

Sep 13, 2021

RheumNow Podcast – High Science and Future Treatments (9.10.2021)

Sep 10, 2021

This week: high science that affect future treatments; breakthrough infections in our patients, and what's up with that; and soon your radiologist is going to be replaced by AI. This and more in our review of the news and journal articles from the past week.

Read Article
×